1. Copyright © 2015 American Medical Association. All rights reserved.
From: Evaluating Expected Costs and Benefits of Granting Access to New Treatments on the Basis of Progression-Free Survival in Non–Small-Cell Lung Cancer
JAMA Oncol. 2015;1(2): doi: /jamaoncol
Figure Legend:
Expected Net Overall Survival (OS) Benefit per Patient by Minimum Progression-Free Survival (PFS) ThresholdExpected per-patient net OS benefit is calculated using the described quantitative framework. The sample sizes displayed were calculated by summing trial populations across all studies that met each PFS threshold.
Date of download: 10/11/2017
Copyright © 2015 American Medical Association. All rights reserved.

2. Copyright © 2015 American Medical Association. All rights reserved.
From: Evaluating Expected Costs and Benefits of Granting Access to New Treatments on the Basis of Progression-Free Survival in Non–Small-Cell Lung Cancer
JAMA Oncol. 2015;1(2): doi: /jamaoncol
Figure Legend:
Incremental Social Value of Granting Early Access Based on Progression-Free Survival (PFS) DataIncremental social value is calculated using the described quantitative framework. These calculations use medium patient benefit parameters of $22 000 for incremental lifetime treatment cost and 22 months of delay between PFS and OS evidence publications.
Date of download: 10/11/2017
Copyright © 2015 American Medical Association. All rights reserved.

3. Copyright © 2015 American Medical Association. All rights reserved.
From: Evaluating Expected Costs and Benefits of Granting Access to New Treatments on the Basis of Progression-Free Survival in Non–Small-Cell Lung Cancer
JAMA Oncol. 2015;1(2): doi: /jamaoncol
Figure Legend:
Break-Even Analysis of Policies That Grant Access Based on Alternative Progression-Free Survival (PFS) Benefit ThresholdsFor parameter values below and to the right of each line, it is better to grant access based on PFS data alone, given the particular PFS threshold illustrated. For values above and to the left of each line, it is better to wait for overall survival (OS) data before providing access. Dashed horizontal lines correspond to “high treatment cost,” which is our upper bound cost estimate ($62 000); “medium treatment cost,” which is our mean estimate ($22 000); and “low treatment cost,” which is our lower bound ($2000).
Date of download: 10/11/2017
Copyright © 2015 American Medical Association. All rights reserved.